IMM124E – May offer a new modality of inhibition of



Key points

  • Monash University Research Update at SARS-CoV-2 program
  • Biomedicine Discovery Institute starts a program to isolate and identify inhibitor molecule (s) in IMM-124E
  • Chief Medical Officer Appointment with Preliminary Focus on COVID-19

MELBOURNE, Australia, May 13, 2021 (GLOBE NEWSWIRE) – Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on the development and commercialization of oral immunotherapeutics for the prevention and treatment of intestinal pathogens , today is pleased to provide shareholders and the market with an update on the antiviral activity of IMM124E used to make the company’s flagship product, commercially available immune supplements for gastrointestinal and digestive health and over-the-counter Travelan® and Protectyn®. Scientists at Monash University of the Biomedicine Discovery Institute have developed and optimized two new immuno-based assays using two recombinant reagents, the Spike SARS-CoV-2 protein and a receptor binding domain protein obtained from the Peter Doherty Institute for Infection and Immunity of Melbourne.

Preliminary results (ASX announcement dated July 21, 2020) previously reported investigating IMM-124E demonstrated neutralizing activity against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the virus that causes COVID-19. Other studies now being undertaken by Monash suggest that the inhibitory activity of SARS-CoV-2 is new and does not bind to the spike protein or receptor-binding domain that the virus uses to attach to cells it quits. ‘it infects.

SARS-CoV-2 and Bovine Corona (BCoV) viruses are closely related phylogenetically. Different studies have demonstrated the existence of cross immunity through sites / epitopes shared between bovine and human viruses. Thus, it appears that the immunological homology in the highly conserved structures between the two viruses may be the cause of the inhibition reported. The immune recognition of the viral structural proteins M and S2, by the anti-BCoV antibodies present in IMM-124E could cause inactivation of the SARS-COV-2 virus.

This antiviral effect differs from most vaccines currently in development that directly target the spike protein. The mode of action may offer a complementary treatment regimen using therapies targeting the virus.

“Our first results suggest that the inhibitory substance (s) contained in the products bind to other antigens present on the SARS-CoV-2 virus which interfere with the mechanism used by the virus to enter and infect human cells. We do not yet know which compound (s) in the products are responsible for this interference. However, we are happy to try to identify them, ”said Professor Lyras.

Prof Lyras added: “It doesn’t matter whether SARS-CoV-2 virus antagonists block spike protein binding directly or indirectly as long as they can prevent or reduce infection.”

The research team now plans to try to isolate and identify the inhibitor molecule (s) in IMM124E.

The company is also pleased to announce the appointment of Dr Dan Peres as Chief Medical Officer. Dr Peres will be responsible for leading and managing the company’s clinical development programs with a focus on COVID-19. Dr Peres was previously hired by Immuron to manage the Company-sponsored Phase II NASH clinical trial.

This press release has been authorized by the directors of Immuron Limited.

COMPALL CONTACT:

Dr Jerry Kanellos, Ph.D.
Chief executive officer
Phone. : +61 (0) 3 9824 5254
[email protected]

For more information visit: http://www.immuron.com



Source link

Previous Immunome Reports First Quarter 2021 Financial Results
Next Emerging Stronger Taskforce: S'pore Can Unlock "Virtually Endless Opportunities" By Playing On Its Strengths, Singapore News & Top Stories

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *